The pill on the menu
For the first time there is an FDA-approved GLP-1 you swallow, and it has started showing up in the same dropdown menus as the injections. Here is what a tablet actually changes for women managing PMOS (PCOS) — and the parts of the problem it leaves exactly where they were.
Before anything else
We write; we do not prescribe. Nothing below is a recommendation to start, stop, or switch anything, and a medication being newly available says nothing about whether it belongs in your body. Bring this to a clinician who knows your history. On we go.
In April the FDA approved orforglipron, sold as Foundayo, and the sentence that made everyone look up was the boring one: no food or water restrictions. You take it whenever. That sounds like a footnote until you have spent a year building your morning around a tablet that demands an empty stomach and a thirty-minute wait before coffee.
It arrives in six tablet strengths and, on paper, at prices that undercut a lot of what women have been quietly paying. Self-pay starts around $149 a month at the lowest dose. With commercial coverage and the manufacturer's savings card, some patients land near $25. Medicare Part D beneficiaries have had a $50 route since the start of July. It is stocked through the manufacturer's own delivery service, through retail pharmacies, and — the part that matters for anyone reading a comparison site — through telehealth.
That last one happened faster than we expected. Menus that listed four injectables in the spring now list a tablet alongside them, and at least two of the women's-health platforms in our comparison put it in front of you before you have finished the intake form.
What a tablet genuinely solves
Three real things, and we do not want to undersell them.
The first is the needle. Some women are fine with weekly injections and some are not, and the ones who are not have mostly been told to get over it. A swallowed dose removes that conversation entirely.
The second is the cold chain. Vials want refrigeration, which means travel logistics, which means a summer of hotel mini-fridges and a small ongoing anxiety about whether a shipment sat on a porch in July. Tablets do not care.
The third is quieter. A prescription filled at the pharmacy down the road, under an approved brand name, is legible to every other clinician you see. It shows up in your chart the way any other medication does. For women who have spent years being second-guessed about their own care, that legibility has a value the price sheet does not capture.
A pill removes a set of practical obstacles. It does not remove the reason you were looking for a GLP-1 in the first place.
What it does not solve
Now the part that gets skipped in the launch coverage.
Orforglipron acts on the GLP-1 receptor alone. Tirzepatide acts on two — GLP-1 and GIP — which is a meaningful pharmacological difference, not a marketing one. Whether that difference matters for you is a clinical question with a real answer, and the answer depends on your body rather than on which molecule had the better press release.
More to the point for this site: there is no PMOS (PCOS)-specific trial data behind it. None. It is approved for obesity, which is not the same as being studied in women whose insulin resistance is driving androgen production and irregular cycles. Everything we said in One in six about the gap between prescribing volume and condition-specific evidence applies here with more force, because the drug is newer.
And it is still a GLP-1. The gastrointestinal side effects that made you research this in the first place do not become gentler because the delivery is oral. Daily dosing also means daily adherence, which is a different discipline than remembering one injection a week — easier for some people, harder for others, and worth being honest with yourself about which you are.
The question underneath the format
Here is what we keep coming back to. The format of the medication is one of the least important variables in whether this works for you. Whether the person prescribing it understands that PMOS (PCOS) is a metabolic condition, whether they will read your labs and your cycle history together instead of separately, whether anyone will answer you at week three when the nausea is bad, whether there is a plan for what happens after — those decide the outcome. A pill prescribed by someone who is not paying attention is still a prescription from someone who is not paying attention.
So if a new option has you reconsidering your provider, reconsider the provider on the things that were always going to matter. That is the entire reason we grade what we grade. The Care Standard does not have a row for injection versus tablet, and we are not planning to add one.
If you want to ask about it
A few questions that tend to get useful answers. Is there evidence for this specific molecule in women with PMOS (PCOS), or are we extending general obesity data to me? Given my insulin resistance, is a single-receptor drug the right tool, or is there a reason to prefer a dual one? What are we measuring besides weight — and when will we know? And if this is not the right fit at month three, what is the plan then?
A provider who treats the condition rather than the number will have somewhere to go with all four.
The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a recommendation, and not a prediction about your results. No GLP-1 is FDA-approved specifically for PMOS (PCOS), and GLP-1 medications are not a treatment for endometriosis; references to endometriosis on this site describe whole-woman clinical context, never a therapy for the condition. Prices and availability change constantly — confirm them with the provider. Selene is editorial: we do not prescribe, sell, or dispense anything.